Search

Your search keyword '"Giannakakou, Paraskevi"' showing total 561 results
Start Over Author "Giannakakou, Paraskevi"
561 results on '"Giannakakou, Paraskevi"'

1. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement

Author

Gjyrezi, Ada, Xie, Fang, Voznesensky, Olga, Khanna, Prateek, Calagua, Carla, Bai, Yang, Kung, Justin, Wu, Jim, Corey, Eva, Montgomery, Bruce, Mace, Sandrine, Gianolio, Diego A., Bubley, Glenn J., Balk, Steven P., Giannakakou, Paraskevi, and Bhatt, Rupal S.

Subjects
Sanofi S.A., Cabazitaxel, Tubulin, Enzalutamide, Abiraterone, Medical research, Prostate cancer -- Drug therapy, Pharmaceutical industry, Cancer metastasis -- Drug therapy, Health care industry, Beth Israel Deaconess Medical Center
Abstract

Despite widespread use of taxanes, mechanisms of action and resistance in vivo remain to be established, and there is no way of predicting who will respond to therapy. This study examined prostate cancer (PCa) xenografts and patient samples to identify in vivo mechanisms of taxane action and resistance. Docetaxel drug- target engagement was assessed by confocal anti-tubulin immunofluorescence to quantify microtubule bundling in interphase cells and aberrant mitoses. Tumor biopsies from metastatic PCa patients obtained 2 to 5 days after their first dose of docetaxel or cabazitaxel were processed to assess microtubule bundling, which correlated with clinical response. Microtubule bundling was evident in PCa xenografts 2 to 3 days after docetaxel treatment but was decreased or lost with acquired resistance. Biopsies after treatment with leuprolide plus docetaxel showed extensive microtubule bundling as did biopsies obtained 2 to 3 days after initiation of docetaxel or cabazitaxel in 2 patients with castration-resistant PCa with clinical responses. In contrast, microtubule bundling in biopsies 2 to 3 days after the first dose of docetaxel was markedly lower in 4 nonresponding patients. These findings indicate that taxanes target both mitotic and interphase cells in vivo and that resistance is through mechanisms that impair drug-target engagement. Moreover, the findings suggest that microtubule bundling after initial taxane treatment may be a predictive biomarker for clinical response., Introduction Taxanes are the only line of chemotherapy shown to prolong survival in men with metastatic castration-resistant prostate cancer (CRPC) who have progressed after standard androgen deprivation therapy (ADT, surgical [...]

Published
2020
Full Text
View/download PDF

2. Microtubules in Prostate Cancer

Author

Giannakakou, Paraskevi (Evi), Galletti, Giuseppe, Cagle, Philip T., Series editor, Robinson, Brian D., editor, Mosquera, Juan Miguel, editor, Ro, Jae Y., editor, and Divatia, Mukul, editor

Published
2018
Full Text
View/download PDF

5. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation

Author

Zhang, Haiying, Freitas, Daniela, Kim, Han Sang, Fabijanic, Kristina, Li, Zhong, Chen, Haiyan, Mark, Milica Tesic, Molina, Henrik, Martin, Alberto Benito, Bojmar, Linda, Fang, Justin, Rampersaud, Sham, Hoshino, Ayuko, Matei, Irina, Kenific, Candia M., Nakajima, Miho, Mutvei, Anders Peter, Sansone, Pasquale, Buehring, Weston, Wang, Huajuan, Jimenez, Juan Pablo, Cohen-Gould, Leona, Paknejad, Navid, Brendel, Matthew, Manova-Todorova, Katia, Magalhães, Ana, Ferreira, José Alexandre, Osório, Hugo, Silva, André M., Massey, Ashish, Cubillos-Ruiz, Juan R., Galletti, Giuseppe, Giannakakou, Paraskevi, Cuervo, Ana Maria, Blenis, John, Schwartz, Robert, Brady, Mary Sue, Peinado, Héctor, Bromberg, Jacqueline, Matsui, Hiroshi, Reis, Celso A., and Lyden, David

Published
2018
Full Text
View/download PDF

8. Data from Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes

Author

Kanakkanthara, Arun, primary, Wilmes, Anja, primary, O'Brate, Aurora, primary, Escuin, Daniel, primary, Chan, Ariane, primary, Gjyrezi, Ada, primary, Crawford, Janet, primary, Rawson, Pisana, primary, Kivell, Bronwyn, primary, Northcote, Peter T., primary, Hamel, Ernest, primary, Giannakakou, Paraskevi, primary, and Miller, John H., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Tables 1-4, Figures 1-4 from Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes

Author

Kanakkanthara, Arun, primary, Wilmes, Anja, primary, O'Brate, Aurora, primary, Escuin, Daniel, primary, Chan, Ariane, primary, Gjyrezi, Ada, primary, Crawford, Janet, primary, Rawson, Pisana, primary, Kivell, Bronwyn, primary, Northcote, Peter T., primary, Hamel, Ernest, primary, Giannakakou, Paraskevi, primary, and Miller, John H., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

18. Data from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 3 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 4 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 2 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 2 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Author

Tagawa, Scott T., primary, Antonarakis, Emmanuel S., primary, Gjyrezi, Ada, primary, Galletti, Giuseppe, primary, Kim, Seaho, primary, Worroll, Daniel, primary, Stewart, John, primary, Zaher, Atef, primary, Szatrowski, Ted P., primary, Ballman, Karla V., primary, Kita, Katsuhiro, primary, Tasaki, Shinsuke, primary, Bai, Yang, primary, Portella, Luigi, primary, Kirby, Brian J., primary, Saad, Fred, primary, Eisenberger, Mario A., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Video 2 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure Legend from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

31. Data from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase

Author

Marcus, Adam I., primary, Zhou, Jun, primary, O'Brate, Aurora, primary, Hamel, Ernest, primary, Wong, Jason, primary, Nivens, Michael, primary, El-Naggar, Adel, primary, Yao, Tso-Pang, primary, Khuri, Fadlo R., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase

Author

Marcus, Adam I., primary, Zhou, Jun, primary, O'Brate, Aurora, primary, Hamel, Ernest, primary, Wong, Jason, primary, Nivens, Michael, primary, El-Naggar, Adel, primary, Yao, Tso-Pang, primary, Khuri, Fadlo R., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Video 1 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase

Author

Marcus, Adam I., primary, Zhou, Jun, primary, O'Brate, Aurora, primary, Hamel, Ernest, primary, Wong, Jason, primary, Nivens, Michael, primary, El-Naggar, Adel, primary, Yao, Tso-Pang, primary, Khuri, Fadlo R., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure Legends from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase

Author

Marcus, Adam I., primary, Zhou, Jun, primary, O'Brate, Aurora, primary, Hamel, Ernest, primary, Wong, Jason, primary, Nivens, Michael, primary, El-Naggar, Adel, primary, Yao, Tso-Pang, primary, Khuri, Fadlo R., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

50. CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement

Author

National Institutes of Health (US), Weill Cornell Medicine, Ministerio de Economía y Competitividad (España), Kita, Katsuhiro [0000-0001-7392-1722], Galletti, Giuseppe [0000-0002-1920-5554], Madhukar, Neel [0000-0002-2907-2062], Barasoain, Isabel [0000-0003-2013-085X], Holly V., Goodson [0000-0001-7942-8349], Sackett, Dan L. [0000-0002-3492-1866], Díaz, José Fernando [0000-0003-2743-3319], Molina, Henrik [0000-0001-8950-4990], Elemento, Olivier [0000-0002-8061-9617], Giannakakou, Paraskevi [0000-0001-7378-262X], Thakkar, Prashant V., Kita, Katsuhiro, Del Castillo, Urko, Galletti, Giuseppe, Madhukar, Neel, Vila Navarro, Elena, Barasoain, Isabel, Goodson, Holly V., Sackett, Dan L., Díaz, José Fernando, Lu, Yao, RoyChoudhary, Arindam, Molina, Henrik, Elemento, Olivier, Shah, Manish A., Giannakakou, Paraskevi, National Institutes of Health (US), Weill Cornell Medicine, Ministerio de Economía y Competitividad (España), Kita, Katsuhiro [0000-0001-7392-1722], Galletti, Giuseppe [0000-0002-1920-5554], Madhukar, Neel [0000-0002-2907-2062], Barasoain, Isabel [0000-0003-2013-085X], Holly V., Goodson [0000-0001-7942-8349], Sackett, Dan L. [0000-0002-3492-1866], Díaz, José Fernando [0000-0003-2743-3319], Molina, Henrik [0000-0001-8950-4990], Elemento, Olivier [0000-0002-8061-9617], Giannakakou, Paraskevi [0000-0001-7378-262X], Thakkar, Prashant V., Kita, Katsuhiro, Del Castillo, Urko, Galletti, Giuseppe, Madhukar, Neel, Vila Navarro, Elena, Barasoain, Isabel, Goodson, Holly V., Sackett, Dan L., Díaz, José Fernando, Lu, Yao, RoyChoudhary, Arindam, Molina, Henrik, Elemento, Olivier, Shah, Manish A., and Giannakakou, Paraskevi

Abstract

Taxanes are widely used cancer chemotherapeutics. However, intrinsic resistance limits their efficacy without any actionable resistance mechanism. We have discovered a microtubule (MT) plus-end-binding CLIP-170 protein variant, hereafter CLIP-170S, which we found enriched in taxane-resistant cell lines and patient samples. CLIP-170S lacks the first Cap-Gly motif, forms longer comets, and impairs taxane access to its MT luminal binding site. CLIP-170S knockdown reversed taxane resistance in cells and xenografts, whereas its re-expression led to resistance, suggesting causation. Using a computational approach in conjunction with the connectivity map, we unexpectedly discovered that Imatinib was predicted to reverse CLIP-170S-mediated taxane resistance. Indeed, Imatinib treatment selectively depleted CLIP-170S, thus completely reversing taxane resistance. Other RTK inhibitors also depleted CLIP-170S, suggesting a class effect. Herein, we identify CLIP-170S as a clinically prevalent variant that confers taxane resistance, whereas the discovery of Imatinib as a CLIP-170S inhibitor provides novel therapeutic opportunities for future trials.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results